PDS Biotechnology (PDSB) Competitors $2.09 -0.11 (-5.00%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PDSB vs. INO, SELB, CYRX, SAGE, VYGR, CMPS, ITOS, CCCC, PRQR, and ACRSShould you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), Cryoport (CYRX), Sage Therapeutics (SAGE), Voyager Therapeutics (VYGR), COMPASS Pathways (CMPS), iTeos Therapeutics (ITOS), C4 Therapeutics (CCCC), ProQR Therapeutics (PRQR), and Aclaris Therapeutics (ACRS). PDS Biotechnology vs. Inovio Pharmaceuticals Selecta Biosciences Cryoport Sage Therapeutics Voyager Therapeutics COMPASS Pathways iTeos Therapeutics C4 Therapeutics ProQR Therapeutics Aclaris Therapeutics PDS Biotechnology (NASDAQ:PDSB) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability. Do institutionals and insiders hold more shares of PDSB or INO? 26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 9.5% of PDS Biotechnology shares are owned by insiders. Comparatively, 2.5% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, PDSB or INO? PDS Biotechnology has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Do analysts prefer PDSB or INO? PDS Biotechnology presently has a consensus price target of $12.33, suggesting a potential upside of 490.11%. Inovio Pharmaceuticals has a consensus price target of $38.00, suggesting a potential upside of 833.66%. Given Inovio Pharmaceuticals' higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than PDS Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Inovio Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is PDSB or INO more profitable? Inovio Pharmaceuticals' return on equity of -118.17% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -139.57% -67.22% Inovio Pharmaceuticals N/A -118.17%-83.47% Does the media prefer PDSB or INO? In the previous week, Inovio Pharmaceuticals had 18 more articles in the media than PDS Biotechnology. MarketBeat recorded 19 mentions for Inovio Pharmaceuticals and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.61 beat Inovio Pharmaceuticals' score of 0.16 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Overall Sentiment PDS Biotechnology Positive Inovio Pharmaceuticals Neutral Does the MarketBeat Community favor PDSB or INO? Inovio Pharmaceuticals received 650 more outperform votes than PDS Biotechnology when rated by MarketBeat users. Likewise, 71.19% of users gave Inovio Pharmaceuticals an outperform vote while only 69.00% of users gave PDS Biotechnology an outperform vote. CompanyUnderperformOutperformPDS BiotechnologyOutperform Votes6969.00% Underperform Votes3131.00% Inovio PharmaceuticalsOutperform Votes71971.19% Underperform Votes29128.81% Which has stronger valuation and earnings, PDSB or INO? PDS Biotechnology has higher earnings, but lower revenue than Inovio Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$42.94M-$1.16-1.80Inovio Pharmaceuticals$830K127.98-$135.12MN/AN/A SummaryPDS Biotechnology beats Inovio Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Ad Insiders Exposed917 Trades… Zero Losses?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PDSB vs. The Competition Export to ExcelMetricPDS BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.19M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-1.8011.10105.1417.83Price / SalesN/A362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book3.5410.377.096.50Net Income-$42.94M$153.60M$119.65M$226.22M7 Day Performance3.98%4.60%2.25%4.03%1 Month Performance-32.91%-6.29%-2.33%4.92%1 Year Performance-66.07%33.41%33.98%29.30% PDS Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PDSBPDS Biotechnology1.852 of 5 stars$2.09-5.0%$12.33+490.1%-66.1%$78.19MN/A-1.8020INOInovio Pharmaceuticals3.3874 of 5 stars$4.17+2.7%$38.00+811.3%-93.1%$108.84M$830,000.000.00127Analyst RevisionSELBSelecta BiosciencesN/AN/AN/AN/A$136.76M$110.78M-4.0164Gap DownHigh Trading VolumeCYRXCryoport2.8687 of 5 stars$6.44-1.2%$12.50+94.1%-53.2%$318.34M$226.11M-1.951,170Insider TradeSAGESage Therapeutics4.3758 of 5 stars$5.11+5.4%$12.83+151.1%-73.4%$312.59M$106.40M-0.87690Analyst ForecastVYGRVoyager Therapeutics4.6684 of 5 stars$5.67+4.4%$17.00+199.8%-17.8%$309.73M$163.78M7.97100CMPSCOMPASS Pathways2.9186 of 5 stars$4.51+1.3%$30.67+580.0%-27.1%$308.57MN/A-2.03120Positive NewsITOSiTeos Therapeutics3.5107 of 5 stars$8.38+3.1%$31.50+275.9%-14.2%$306.12M$12.60M-2.5990CCCCC4 Therapeutics2.0493 of 5 stars$4.26+6.2%$10.00+134.7%+179.6%$300.71M$20.76M-2.52150News CoveragePRQRProQR Therapeutics2.0955 of 5 stars$3.65+1.1%$7.13+95.2%+151.4%$298.13M$7.05M-11.31180News CoverageACRSAclaris Therapeutics3.8433 of 5 stars$4.09-5.3%$8.80+115.2%+366.7%$292.15M$27.08M-8.3186Analyst UpgradeInsider TradeAnalyst Revision Related Companies and Tools Related Companies INO Competitors SELB Competitors CYRX Competitors SAGE Competitors VYGR Competitors CMPS Competitors ITOS Competitors CCCC Competitors PRQR Competitors ACRS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PDSB) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
